Longeveron earnings release, August 12, 2026
Exhibit
99.1
Longeveron
Announces 2026 Second Quarter Financial Results and Provides Business Update
MIAMI,
Fla., August 12, 2026 -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended June 30, 2026 and provided a business update.
“Longeveron is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have the potential to redefine the trajectory of our business,” said Stephen H. Willard, Chief Executive Officer of Longeveron. “Our approach to stem cell therapy development has garnered external recognition and validation with positive clinical data having been published in
Nature Medicine and
Cell Stem Cell and also serving as the foundation for our selection as a Finalist for the XPRIZE
Healthspan competition out of over 600 projects submitted worldwide. We are rapidly approaching the September top line data readout of our ELPIS II Phase 2b clinical trial evaluating laromestrocel in HLHS and look forward to sharing those results.”
Development
Programs
Longeveron’s investigational therapeutic candidate laromestrocel (Lomecel-B®) is a proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications.
Hypoplastic
Left Heart Syndrome (HLHS) – a rare pediatric congenital heart birth defect in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing.
Pediatric
Dilated Cardiomyopathy (PDCM) – a rare pediatric cardiovascular disease in which the muscles in one or more of the heart chambers become enlarged or stretched (dilated), with nearly 40% of children with PDCM requiring a heart transplant or dying within two years of diagnosis.
Alzheimer’s disease (AD) – a neurodegenerative disorder that leads to progressive memory loss and death and currently has very limited therapeutic options..
Aging-related
Frailty (AF) – a chronic condition driven by systemic physiologic decline, characterized by reduced reserve and resilience across multiple organ systems with common features including weakness, fatigue, weight loss, slowness and reduced activity. No FDA-approved therapies currently exist.
Corporate
Updates²
2026
Second Quarter Summary Financial Results
Clinical trial revenue, which is derived from The Bahamas Registry Trial, for each of the three-month periods ended June 30, 2026 and June 30,
2025 was $0.3 million. Contract manufacturing revenues for the three months ended June 30, 2026 and 2025, were $0 and $18,000, respectively.
This decrease of $18,000, or 100%, when compared to the same period in 2025, was driven by the absence of any additional contract manufacturing services from our third-party client.
Related cost of revenues were $0.1 million and $0.2 million for the three months ended June 30, 2026 and 2025, respectively. This resulted in a gross profit of approximately $0.2 million for the three months ended June 30, 2026, an increase of $36,000, or 25%, when compared to 2025.
Conference
Call and Webcast Details:
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.³
About
Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric
Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important
U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Forward-Looking
Statements
Financial statements
Income Statement
Three months ended June 30, — (Unaudited) (in thousands)
| Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenues | Clinical trial revenue | 287 | 298 | 665 | 557 |
| Revenues | Contract manufacturing lease revenue | 6 | 12 | ||
| Revenues | Contract manufacturing revenue | 12 | 20 | 128 | |
| Revenues | Total revenues | 287 | 316 | 685 | 697 |
| Revenues | Cost of revenues | 105 | 170 | 239 | 276 |
| Revenues | Gross profit | 182 | 146 | 446 | 421 |
| Operating expenses | General and administrative | 3,159 | 2,589 | 5,879 | 5,530 |
| Operating expenses | Research and development | 3,194 | 2,954 | 5,513 | 5,469 |
| Operating expenses | Total operating expenses | 6,353 | 5,543 | 11,392 | 10,999 |
| Operating expenses | Loss from operations | -6,171 | -5,397 | -10,946 | -10,578 |
| Other income | Other income, net | 98 | 369 | 137 | 539 |
| Other income | Total other income, net | 98 | 369 | 137 | 539 |
| Other income | Net loss | -6,073 | -5,028 | -10,809 | -10,039 |
| Other income | Basic and diluted net loss per share | -0.19 | -0.33 | -0.38 | -0.67 |
| Other income | Basic and diluted weighted average common shares outstanding | 31,377,630 | 15,013,072 | 28,100,164 | 14,982,075 |
Balance Sheet
June 30, 2026 — (In thousands, except share and per share data)
| June 30, 2026 – (Unaudited) | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 10,077 | 4,661 |
| Current assets: | Prepaid expenses and other current assets | 1,181 | 686 |
| Current assets: | Accounts receivable | 65 | 104 |
| Current assets: | Total current assets | 11,323 | 5,451 |
| Current assets: | Property and equipment, net | 1,602 | 1,836 |
| Current assets: | Intangible assets, net | 2,202 | 2,285 |
| Current assets: | Operating lease asset, net | 348 | 513 |
| Current assets: | Other assets | 12 | 176 |
| Current assets: | Total assets | 15,487 | 10,261 |
| Current liabilities: | Accounts payable | 633 | 423 |
| Current liabilities: | Accrued expenses | 2,653 | 2,969 |
| Current liabilities: | Current portion of lease liability | 581 | 655 |
| Current liabilities: | Deferred revenue | 40 | 40 |
| Current liabilities: | Other current liabilities | 400 | |
| Current liabilities: | Total current liabilities | 4,307 | 4,087 |
| Long-term liabilities: | Long-term portion of operating lease liability | 169 | |
| Long-term liabilities: | Liability related to the sale of future PRV proceeds | 778 | |
| Long-term liabilities: | Other liabilities | 330 | |
| Long-term liabilities: | Total long-term liabilities | 778 | 499 |
| Long-term liabilities: | Total liabilities | 5,085 | 4,586 |
| Stockholders’ equity: | Class A common stock, $0.001 par value per share, 175,000,000 shares authorized, 30,269,636 shares issued and outstanding at June 30, 2026; 21,445,336 issued and outstanding at December 31, 2025 | 30 | 21 |
| Stockholders’ equity: | Class B common stock, $0.001 par value per share, 15,705,000 shares authorized, 1,449,005 shares issued and outstanding at June 30, 2026; 1,484,005 shares issued and outstanding at December 31, 2025 | 1 | 1 |
| Stockholders’ equity: | Additional paid-in capital | 153,491 | 137,964 |
| Stockholders’ equity: | Accumulated deficit | -143,120 | -132,311 |
| Stockholders’ equity: | Total stockholders’ equity | 10,402 | 5,675 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 15,487 | 10,261 |
Full release
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,”
“believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,”
“intend,” “looks to,” “may,” “on condition,” “plan,” “potential,”
“predict,” “preliminary,” “project,” “see,” “should,” “target,”
“will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause... (truncated)his release include, but are not limited to, the ability of our clinical trials to demonstrate safety and efficacy of our investigational products, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for our stem cell therapy laromestrocel in our development programs; our ability to reach alignment with the FDA and other regulatory authorities on a potential path toward regulatory approval of our investigational products; receipt of trial results and other available evidence sufficient to support the Company filing a BLA following the readout of top-line results of the ELPIS II data; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the size of the market opportunity for certain of our investigational products, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational products for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational products; our ability to obtain and maintain regulatory approval of our investigational products in the U.S. and other jurisdictions; our plans relating to the further development of our investigational products, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the
Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form
10-Q, and its Current Reports on Form 8-K. The Company operates in a highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor and Media Contact:
Derek
Cole
Investor Relations Advisory Solutions derek.cole@iradvisory.com
---tables follow---⁴
Longeveron
Inc.
Condensed
Balance Sheets
(In thousands, except share and per share data)
See accompanying notes to financial statements.⁵
Longeveron
Inc.
Condensed
Statements of Operations
(In thousands, except per share data)
(Unaudited)
See accompanying notes to financial statements.⁶